18 February 2021
Visiongain has published a new report on Viral Inactivation Market Report 2021-2031: Forecasts by Product (Kits, Reagents, Systems, Services), Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Method (Solvent Detergent, Pasteurization) & End User (Pharmaceutical and Biotechnology, CROs). PLUS Profiles of Leading Pharma Contract Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Viral Inactivation market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.
Viral inactivation is a process viral clearance that is mandatory for any phase of drug development or any process. Food and Drug (FDA) has open the doors for this market by imposing strict regulations in numerous applications such as stem cells products, therapeutics, blood and blood products, tissue and tissue products, cell and gene treatment and vaccines, contributing towards the growth of the market. However, high degree of consolidation to act as a major barrier for new entrants in the viral inactivation market. Small drug manufacturing companies are finding a difficult time in growing themselves. The established market players have established there footprints in the market by all the means which include new product development, mergers and acquisitions, joint venture among others.
COVID-19 Impact on Viral Inactivation Market
The world is suffering with the pandemic COViD-19. All pharmaceuticals company are working on better drug and vaccines. These companies are undergoing with several trails with this drugs, Food and Drug association have imposed strict regulations on these companies to undergo with this process of viral inactivation. So this market is likely to boost in this period of pandemic COViD-19.
- Increasing number of drugs launching are driving this market towards growth.
- Rapid growth of Pharmaceuticals Company and biotechnological industries is taking this market towards growth.
- The growth of this market depends on surging R&D innovations and FDA allowance leads to commercialization of new drug.
- Growing government support for the biotechnology and pharmaceutical industries across the globe drives this market growth.
The Global viral Inactivation market is very likely to grow in the future, due to the increase in drugs in all fields, increasing pharmaceuticals companies and biotechnology industries. Regulations imposed on this companies to undergo this process of viral inactivation, and encouraging government policies is giving a boost to this sector.
Global Viral Inactivation market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions and others to increase their footprints in this market.
Some of the companies are mentioned
Danaher, MerckKgaA, Parker Hannifin CORP, Sartorius Ag, SGS SA, Charles River, Clean Cells, Radsource Technologies, Texcell, WuXi Apptec.
The majority of the players are focusing on the introduction of new products. Mergers and acquisitions are frequently seen in the market resulting in a high degree of market amalgamation. For instance, in August 2015, Danaher Corporation completed the acquisition of Pall Corporation, a leading provider of virus clearance and inactivation products.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
14 September 2023
The global Stem Cell Therapy Contract Manufacturing market was valued at US$2,495.1 million in 2022 and is projected to grow at a CAGR of 12.4% during the forecast period 2023-2033.
13 September 2023
Immuno-Oncology Clinical Trials market is valued at US$6,849.8 million in 2023 and is projected to grow at a CAGR of 11.3% during the forecast period 2023-2033.